SCHEDULE 13D
This Amendment No. 2 (Amendment) amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission (the
SEC) on June 11, 2018, as amended by Amendment No. 1 filed with the SEC on January 27, 2020 (collectively, the Original Schedule 13D), by New Leaf Ventures III, L.P. (NLV III), New Leaf Venture
Associates III, L.P. (NLV Associates III), New Leaf Biopharma Opportunities II, L.P. (Biopharma II), New Leaf BPO Associates II, L.P. (NLBA II), New Leaf Venture Management III, L.L.C. (NLV Management
III), New Leaf BPO Management II, L.L.C. (NLB Management II), Ronald M. Hunt, a member of the Issuers board of directors (Hunt), and Vijay K. Lathi (Lathi, and collectively with the foregoing entities
and individuals, the Reporting Persons). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed
incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.
Item 5. Interest in Securities of the Issuer.
(a,b)
Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person and the corresponding footnotes. Regarding sole power
to vote shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 9 of the cover page of each
Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.
Each of the Reporting Persons,
except for (i) NLV III with respect to the shares directly owned by it, (ii) Biopharma II with respect to the shares directly owned by it and (iii) Hunt with respect to the shares directly owned by him, disclaims beneficial ownership
of such shares for all purposes, except to the extent of their respective pecuniary interests therein, if any.
(e) The Reporting Persons ceased to be the
beneficial owners of more than five percent of the Companys Ordinary Shares on December 31, 2020.
Item 7. Material to be Filed as
Exhibits.
Exhibit A Joint Filing Agreement